Abstract:The clinical application of chimeric antigen receptor (CAR) T‐cell therapy has rapidly changed the treatment options for terminally ill patients with defined blood‐borne cancer types. However, CAR T‐cell therapy can lead to severe therapy‐associated toxicities including CAR‐related hematotoxicity, ON‐target OFF‐tumor toxicity, cytokine release syndrome (CRS) or immune effector cell‐associated neurotoxicity syndrome (ICANS). Just as CAR T‐cell therapy has evolved regarding receptor design, gene transfer systems and production protocols, the management of side effects has also improved. However, because of measures taken to abrogate adverse events, CAR T‐cell viability and persistence might be impaired before complete remission can be achieved. This has fueled efforts for the development of extrinsic and intrinsic strategies for better control of CAR T‐cell activity. These approaches can mediate a reversible resting state or irreversible T‐cell elimination, depending on the route chosen. Control can be passive or active. By combination of CAR T‐cells with T‐cell inhibiting compounds, pharmacologic control, mostly independent of the CAR construct design used, can be achieved. Other strategies involve the genetic modification of T‐cells or further development of the CAR construct by integration of molecular ON/OFF switches such as suicide genes. Alternatively, CAR T‐cell activity can be regulated intracellularly through a self‐regulation function or extracellularly through titration of a CAR adaptor or of a priming small molecule. In this work, we review the current strategies and mechanisms to control activity of CAR T‐cells reversibly or irreversibly for preventing and for managing therapy‐associated toxicities.

Direct control of CAR T cells through small molecule-regulated antibodies

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

Versatile strategy for controlling the specificity and activity of engineered T cells

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Small molecule-regulated switches to provide functional control of CAR T cells within the patient

Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand

Switch-mediated Activation and Retargeting of CAR-T Cells for B-cell Malignancies

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function

Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety

Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control

Engineering programmable CAR-T cells with tunable controls as fail-safe mechanisms during cancer immunotherapy

Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

From Therapeutic Antibodies to Chimeric Antigen Receptors (cars): Making Better CARs Based on Antigen-Binding Domain

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Aptamer-Based Nongenetic Reprogramming of CARs Enables Flexible Modulation of T Cell-Mediated Tumor Immunotherapy

Enhancing the Safety of CAR-T Cell Therapy: Synthetic Genetic Switch for Spatiotemporal Control.

A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T Cells

Co-opting signalling molecules enables logic-gated control of CAR T cells

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors